Search hospitals > Texas > Fort Worth
UT Southwestern/Simmons Cancer Center-Fort Worth
Claim this profileFort Worth, Texas 76104
Global Leader in Lung Cancer
Global Leader in Non-Small Cell Lung Cancer
Conducts research for Bladder Cancer
Conducts research for Kidney Cancer
Conducts research for Breast Cancer
76 reported clinical trials
28 medical researchers
Summary
UT Southwestern/Simmons Cancer Center-Fort Worth is a medical facility located in Fort Worth, Texas. This center is recognized for care of Lung Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Kidney Cancer, Breast Cancer and other specialties. UT Southwestern/Simmons Cancer Center-Fort Worth is involved with conducting 76 clinical trials across 202 conditions. There are 28 research doctors associated with this hospital, such as David Miller, MD, Syed M. Kazmi, Suzanne M. Cole, and Tian Zhang, MD.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
David Miller, MDParkland Memorial Hospital3 years of reported clinical research
Studies Ovarian Cancer
Studies Cervical Cancer
21 reported clinical trials
40 drugs studied
Syed M. KazmiUT Southwestern/Simmons Cancer Center-Dallas8 years of reported clinical research
Studies Colon Cancer
Studies Colorectal Cancer
17 reported clinical trials
33 drugs studied
Suzanne M. ColeUT Southwestern/Simmons Cancer Center-Dallas5 years of reported clinical research
Studies Bladder Cancer
Studies Kidney Cancer
16 reported clinical trials
38 drugs studied
Tian Zhang, MDUniversity of Texas Southwestern Medical Center at Dallas1 year of reported clinical research
Studies Renal Cell Carcinoma
Studies Kidney Cancer
11 reported clinical trials
14 drugs studied
Clinical Trials running at UT Southwestern/Simmons Cancer Center-Fort Worth
Bladder Cancer
Lung Cancer
Kidney Cancer
Prostate Cancer
Skin Cancer
Bladder Carcinoma
Uterine Cancer
Pancreatic Cancer
Pancreatic Carcinoma
Ovarian Cancer
Disitamab Vedotin + Pembrolizumab vs Chemotherapy
for Bladder Cancer
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting2 awards Phase 3
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
Blood Test and Immunotherapy
for Bladder Cancer
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.
Recruiting1 award Phase 2 & 310 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at UT Southwestern/Simmons Cancer Center-Fort Worth?
UT Southwestern/Simmons Cancer Center-Fort Worth is a medical facility located in Fort Worth, Texas. This center is recognized for care of Lung Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Kidney Cancer, Breast Cancer and other specialties. UT Southwestern/Simmons Cancer Center-Fort Worth is involved with conducting 76 clinical trials across 202 conditions. There are 28 research doctors associated with this hospital, such as David Miller, MD, Syed M. Kazmi, Suzanne M. Cole, and Tian Zhang, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.